Novartis Stock Price, News & Analysis (NYSE:NVS)

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis announced an annual dividend on Thursday, January 31st. Shareholders of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a dividend yield of 3.27%. The ex-dividend date of this dividend is Monday, March 4th. This is a positive change from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.

Novartis AG (NYSE:NVS) released its earnings results on Thursday, July, 18th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.14. The company had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $11.45 billion. Novartis had a net margin of 23.27% and a return on equity of 18.55%. Novartis's revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.29 earnings per share. View Novartis' Earnings History.

Novartis is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Novartis.

12 brokers have issued twelve-month price objectives for Novartis' shares. Their predictions range from $79.16 to $105.00. On average, they anticipate Novartis' share price to reach $91.94 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Price Targets for Novartis.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 4 sell ratings, 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Media stories about NVS stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Novartis earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Novartis.

Novartis saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 3,110,000 shares, a decline of 13.1% from the August 30th total of 3,580,000 shares. Based on an average daily trading volume, of 2,000,000 shares, the short-interest ratio is presently 1.6 days. Currently, 0.1% of the company's shares are sold short. View Novartis' Current Options Chain.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Intel (INTC), Walt Disney (DIS), AbbVie (ABBV), NVIDIA (NVDA), Cisco Systems (CSCO), AT&T (T), Gilead Sciences (GILD) and Merck & Co., Inc. (MRK).

Novartis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.11%), Country Trust Bank (0.01%), Gofen & Glossberg LLC IL (0.01%), Scout Investments Inc. (0.01%), Park National Corp OH (0.01%) and Welch & Forbes LLC (0.00%).

NVS stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Manning & Napier Group LLC, Scout Investments Inc., Crossmark Global Holdings Inc., Country Trust Bank, Park National Corp OH, Stonebridge Capital Management Inc. and Measured Wealth Private Client Group LLC.

NVS stock was bought by a variety of institutional investors in the last quarter, including Clarus Wealth Advisors, Pacer Advisors Inc., Grassi Investment Management, We Are One Seven LLC, Bangor Savings Bank, Baldwin Brothers Inc. MA, North Star Investment Management Corp. and Courier Capital LLC.

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVS stock can currently be purchased for approximately $86.60.

Novartis has a market capitalization of $198.47 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.View Additional Information About Novartis.

The official website for Novartis is http://www.novartis.com/.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]